Tianjin First Central Hospital

CancerFax acts as your personal coordinator throughout the entire process. You begin by sharing your medical records — pathology, imaging, biopsy reports, prior treatment summaries — through our secure platform. Our clinical team reviews your case and assesses whether Tianjin First Central Hospital is the right hospital for your specific diagnosis, with particular attention to whether your case fits the strengths of medical oncology, radiation oncology, hepatobiliary surgery, transplant surgery or critical care. We then liaise with the hospital in Chinese to identify the right department, the right consultant and a realistic appointment timeline.

Once a clinical pathway is confirmed, CancerFax prepares a full pre-travel briefing covering expected costs, visa documentation, transport between airport and campus, what to bring on the day, and which campus your appointment will be held at. We remain your single point of contact from first enquiry through to follow-up after treatment. CancerFax charges patients nothing for this navigation service — our role is to remove friction so you can focus on the medical decisions that matter.

Tianjin First Central Hospital's deepest strengths are in liver cancer and hepatobiliary tumours, supported by one of Asia's largest organ transplant programmes — particularly valuable for patients whose liver cancer may be eligible for transplant evaluation. Beyond hepatobiliary disease, the Medical Oncology Department treats lung, breast, oesophageal, gastric, pancreatic, colorectal, cholangiocarcinoma and ovarian cancers, as well as lymphoma, multiple myeloma and leukaemia. The Radiation Oncology Department is suited to head and neck, brain, lung, abdominal, urologic, gynaecologic and bone tumours. If you are unsure whether your diagnosis fits the hospital's strengths, send your records through CancerFax and we will confirm before you make any travel plans.

Yes — this is one of the hospital's most established strengths. The Organ Transplant Center has been operating since 1998 and grew rapidly into one of the largest liver transplant programmes in China, with experience across primary liver cancer, end-stage liver disease, hepatobiliary tumours and complex post-transplant follow-up. The hospital is well placed for patients who need a coordinated evaluation across hepatobiliary surgery, medical oncology, radiation oncology and critical care. CancerFax can help submit your records — imaging, AFP and tumour markers, pathology, prior treatment summary — for the transplant team to assess suitability before you commit to travel.

Yes, in most cases. The standard process is to submit imaging, pathology, treatment history and a current symptom summary — ideally translated into English or with English summaries — to the relevant department through CancerFax. Our team works with the hospital in Chinese to obtain a written specialist opinion or preliminary treatment recommendation. Turnaround typically takes one to two weeks depending on case complexity and which department is reviewing. This is particularly useful for patients considering transplant evaluation, complex radiotherapy planning or a change in systemic therapy, where a structured opinion before travel saves significant time and cost.

As a public Chinese tertiary hospital, consultation and investigation fees at Tianjin First Central Hospital are generally more affordable than comparable specialist centres in North America, Europe or the Gulf. Exact costs vary by department, specialist seniority and whether diagnostic tests such as imaging, pathology review or molecular testing are required on the day. For complex cases — transplant evaluation, advanced radiotherapy planning or detailed multidisciplinary review — additional fees apply for the relevant investigations. CancerFax requests an itemised cost estimate from the hospital as part of your pre-travel package, provided to you at no extra charge and with no mark-up. We can also advise on documentation needed for international insurance claims where applicable.